$200.81
arrow_drop_down0.49%Key Stats | |
---|---|
Open | $202.53 |
Prev. Close | $201.80 |
EPS | 7.94 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
LOW | HIGH | |
---|---|---|
Day Range | 198.55 | 203.24 |
52 Week Range | 189.44 | 269.42 |
Ratios | |
---|---|
EPS | 7.94 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
SAGE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder
SAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology
Cell and Gene Therapy Market Size to Achieve USD 117.46 Bn By 2034
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented